1%, n= 8). Osteopenia, as measured by DEXA, was more severe in OS patients (21.7%, n=13), p=0.01. Liver stiffness (FibroscanR) was higher in patients with OS (median 28.4; IQR 17.3 – 43; p<0.001). Patients of OS predominantly presented with cirrhosis 72.5% (n= 58) as compared to AIH 64.9% (n=113); p = 0.08. At first presentation, 56.3% of OS patients had decompensation in contrast with 37.9% of AIH patients; p−0.03. Overall, patients with OS carried poorer prognosis, as 8.8% died as compared to 5.2% of AIH; p=0.18. The presence of ASMA in the titre of 1:40 or 1:20 was associated with higher incidence of decompensation among patient in

both the groups (p=0.04). Crizotinib supplier The presence of ANA in the titre of 1:40 or 1:80 was negatively associated with decompensation in patients of AIH, but not in case of OS (p = 0.05). CONCLUSIONS: AIH and OS are not uncommon as chronic liver disease in the Indian continent. Patients with OS are older and present more often as cirrhosis with decompensation with a poor prognosis. Decompensation is more likely in patients who harbour ASMA (p= 0.04). We propose that high suspicion in diagnosis and lower threshold in performing liver biopsy in seemingly non-classical AIH would yield early diagnosis and could improve survival benefit in this group. Disclosures: The following people have nothing to disclose: Lovkesh Anand, Cyriac

A. Philips, Varsha Bhat, Chhagan Bihari, Ajeet S. Bhadoria, Shiv

K. Sarin Background/Aim: Autoimmune hepatitis (AIH) type 1, often occurs in middle age females, is a progressive autoimmune liver Sorafenib price disease of unknown pathogenesis. 上海皓元医药股份有限公司 Under the prednisolone (PSL) treatment, the progression of disease is mild in almost patients. However, some patients resist the PSL treatment, and some patients who achieved the remission by the PSL treatment recurrent easily without the PSL treatment. Thus, we analyzed the dynamics of gene expression by PSL treatment including messengerRNA (mRNA), long intergenic non-codingRNA (lin-cRNA), and microRNA (miRNA) in CD4+ T cells to reveal the mechanisms of PSL treatment for AIH. Methods: Clinically and pathologically diagnosed 2 naïve AIHs, 7 AIHs in remission, and 7 healthy controls, who agreed to provide samples with written informed consent, were enrolled in this study. This study was approved by the institutional review board. Total RNA was extracted from CD4+ T cells purified from peripheral blood. The comprehensive analysis of the genes were undergone using microarray with statistics (ANOVA). The data were classified by hierarchical clustering and were analyzed for the function bioinformatically using Gene ontology (GO) analysis and pathway analysis. Results: Microarray study showed that 2,957 mRNAs (p<0.05, fold change>1.5), 574 lincRNAs (p<0.05, fold change>1.5), and 17 miRNAs (p<0.05, fold change>1.2) were differentially expressed among 3 groups.